Merck KGaA Company Profile (NASDAQ:MKGAY)

About Merck KGaA (NASDAQ:MKGAY)

Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ), BioControl Systems Inc and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MKGAY
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $51.06 billion
  • Outstanding Shares: 387,729,000
Average Prices:
  • 50 Day Moving Avg: $38.97
  • 200 Day Moving Avg: $36.37
  • 52 Week Range: $31.28 - $42.02
P/E:
  • Trailing P/E Ratio: 29.99
  • Foreward P/E Ratio: 5.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.6 billion
  • Price / Sales: 0.91
  • Book Value: $12.06 per share
  • Price / Book: 3.25
Dividend:
  • Dividend Yield: 1.1%
Profitability:
  • EBIDTA: $4.99 billion
Misc:
  • Average Volume: 8,163 shs.
 

Frequently Asked Questions for Merck KGaA (NASDAQ:MKGAY)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the NASDAQ under the ticker symbol "MKGAY."

Where is Merck KGaA's stock going? Where will Merck KGaA's stock price be in 2017?

7 brokerages have issued 1 year price objectives for Merck KGaA's stock. Their forecasts range from $57.00 to $73.00. On average, they anticipate Merck KGaA's stock price to reach $65.00 in the next year. View Analyst Ratings for Merck KGaA.

Who are some of Merck KGaA's key competitors?

How do I buy Merck KGaA stock?

Shares of Merck KGaA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck KGaA stock cost?

One share of Merck KGaA stock can currently be purchased for approximately $39.16.

Analyst Ratings

Consensus Ratings for Merck KGaA (NASDAQ:MKGAY) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $65.00 (65.99% upside)

Analysts' Ratings History for Merck KGaA (NASDAQ:MKGAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
10/14/2016Bank of America CorpUpgradeNeutral -> BuyN/AView Rating Details
8/12/2016Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
8/10/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$73.00N/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$53.00 -> $57.00N/AView Rating Details
7/18/2016BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyN/AView Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/AView Rating Details
5/17/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
4/8/2016Nord/LBReiterated RatingBuyN/AView Rating Details
4/8/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
2/6/2016Goldman Sachs Group IncReiterated RatingNeutral$60.00 -> $56.00N/AView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00N/AView Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00N/AView Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralN/AView Rating Details
7/2/2015Piper Jaffray CompaniesReiterated RatingUnderweightN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Merck KGaA (NASDAQ:MKGAY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Merck KGaA (NASDAQ:MKGAY)
Current Year EPS Consensus Estimate: $6.99 EPS
Next Year EPS Consensus Estimate: $6.89 EPS

Dividends

Dividend History for Merck KGaA (NASDAQ:MKGAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merck KGaA (NASDAQ:MKGAY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Merck KGaA (NASDAQ:MKGAY)
Latest Headlines for Merck KGaA (NASDAQ:MKGAY)
Source:
DateHeadline
finance.yahoo.com logoBillionaire George Soros Is Warming Up to This Big Pharma Stock. Should You?
finance.yahoo.com - May 19 at 6:58 PM
nasdaq.com logoMerck KgaA Q1 Profit Down, Sales Rise; Backs FY17 Organic Sales Growth View
www.nasdaq.com - May 19 at 11:06 AM
finance.yahoo.com logo100 Healthy Years - Are Kids Prepared?
finance.yahoo.com - May 19 at 11:06 AM
nasdaq.com logoMerck KgaA Q1 Profit Dips, Adj. EBITDA Rises; Backs FY17 Sales Growth View
www.nasdaq.com - May 18 at 8:32 AM
rttnews.com logoMerck KGaA Plans Measures For Structural Development Of Its Business Sectors
www.rttnews.com - May 17 at 6:30 PM
finance.yahoo.com logoMerck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
finance.yahoo.com - May 17 at 6:30 PM
finance.yahoo.com logoShaping Cancer Care Today and Tomorrow: Merck, KGaA, Darmstadt, Germany, to Present New Data from Rapidly Evolving Pipeline at ASCO 2017
finance.yahoo.com - May 17 at 6:30 PM
seekingalpha.com logoTurmoil In Immuno-Oncology
seekingalpha.com - May 15 at 10:25 AM
seekingalpha.com logoKeytruda Gets Hot And Propels Merck: Analysis
seekingalpha.com - May 11 at 7:04 PM
nasdaq.com logoPfizer : FDA Grants BAVENCIO Approval For Common Type Of Advanced Bladder Cancer
www.nasdaq.com - May 10 at 12:28 PM
rttnews.com logoMerck KGaA : EC Grants Approval For New Pergoveris Pen For Fertility Treatment
www.rttnews.com - May 10 at 12:28 PM
finance.yahoo.com logoHere's Why Vertex Pharmaceuticals Incorporated Gained 8% in April
finance.yahoo.com - May 8 at 6:06 PM
finance.yahoo.com logoVWR Funding, Inc. -- Moody's places VWR on review for downgrade
finance.yahoo.com - May 5 at 6:50 PM
americanbankingnews.com logoMerck KGaA (MKGAY) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 3 at 9:58 AM
finance.yahoo.com logoMerck KGaA : MKGAY-US: Dividend Analysis : May 03rd, 2017 (record date) : By the numbers : May 2, 2017
finance.yahoo.com - May 2 at 4:39 PM
rttnews.com logoMerck Raises Dividend
www.rttnews.com - April 28 at 7:29 PM
seekingalpha.com logoFresenius Shows Biotech How To Get The Deals Done
seekingalpha.com - April 26 at 11:44 PM
finance.yahoo.com logoFresenius and Merck Stocks Top DAX on Biosimilars Deal
finance.yahoo.com - April 25 at 7:26 AM
americanbankingnews.com logoMerck KGaA (MKGAY) Stock Rating Lowered by HSBC Holdings plc
www.americanbankingnews.com - April 7 at 8:05 PM
americanbankingnews.com logoMerck KGaA (MKGAY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 7 at 6:51 PM
seekingalpha.com logoBeiGene, Another Beijing Venture In Cancer Therapy
seekingalpha.com - March 25 at 6:13 PM
rttnews.com logoMerck KGaA : FDA Approves First Treatment For Rare Form Of Skin Cancer
www.rttnews.com - March 24 at 12:08 AM
seekingalpha.com logoFDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
seekingalpha.com - March 23 at 7:06 PM
americanbankingnews.com logoMerck KGaA (MRK) Given a €105.00 Price Target by Goldman Sachs Group Inc Analysts
www.americanbankingnews.com - March 16 at 8:45 AM
americanbankingnews.com logoMerck KGaA (MRK) – Analysts’ Weekly Ratings Changes
www.americanbankingnews.com - March 13 at 5:57 PM
seekingalpha.com logoPfizer And Merck Go For An Even Longer Throw Of The Javelin
seekingalpha.com - March 11 at 12:52 AM
americanbankingnews.com logoMerck KGaA (MRK) Given “Neutral” Rating at JPMorgan Chase & Co.
www.americanbankingnews.com - March 10 at 2:45 PM
americanbankingnews.com logoMerck KGaA (MRK) PT Set at €109.00 by Commerzbank Ag
www.americanbankingnews.com - March 9 at 12:21 PM
nasdaq.com logoMerck KgaA Q4 Profit More Than Doubles; Proposes Higher Dividend
www.nasdaq.com - March 9 at 8:44 AM
rttnews.com logoMerck KgaA Q4 Profit Soars, Sees Stable Earnings In FY17; Stock Dips
www.rttnews.com - March 9 at 8:44 AM
seekingalpha.com logoFDA accepts EMD Serono's BLA for avelumab for urothelial carcinoma; action date August 27
seekingalpha.com - February 28 at 6:41 PM
seekingalpha.com logoMerck KGaA teams up with Domain Therapeutics in immuno-oncology
seekingalpha.com - January 23 at 10:10 AM
seekingalpha.com logoAstra's Mystic Mystery And Other Surprises In Store
seekingalpha.com - January 18 at 7:05 PM
rttnews.com logoMerck KGaA And Palantir Launch New Healthcare Acceleration Partnership
www.rttnews.com - January 13 at 5:07 AM
seekingalpha.com logoVertex to collaborate with Germany's Merck in oncology
seekingalpha.com - January 12 at 12:10 AM
seekingalpha.com logoGerman Merck Unveils Its Secret Weapon
seekingalpha.com - January 10 at 7:27 PM
publicnow.com logoMerck Acquires BioControl to Strengthen Position in Food Safety Testing
us.rd.yahoo.com - January 4 at 7:23 PM
rttnews.com logoMerck KGaA Acquires BioControl Systems
www.rttnews.com - January 4 at 7:23 PM
rttnews.com logoRoche Expands Distribution Agreement With Merck KgaA's Life Science Business
www.rttnews.com - December 1 at 9:37 AM
seekingalpha.com logoRoche expands distribution partnership with Merck KGaA
seekingalpha.com - December 1 at 9:37 AM
seekingalpha.com logoEvotec and Merck KGaA team up to discover new therapeutic targets
seekingalpha.com - November 30 at 11:21 AM
us.rd.yahoo.com logo8:19 am Merck KGaA and Pfizer (PFE) announce that the FDA has accepted for Priority Review MKGAY's BLA for avelumab
us.rd.yahoo.com - November 29 at 2:51 PM
seekingalpha.com logoFDA accepts avelumab BLA under Priority Review for rare type of skin cancer
seekingalpha.com - November 29 at 2:51 PM
seekingalpha.com logoQuintilesIMS forms collaboration with major drug firms to better understand real-world uses of cancer treatments
seekingalpha.com - November 22 at 10:21 AM
msn.com logoGermany's Merck Lifts Full Year Guidance After Sigma-Aldrich Boosts Sales
www.msn.com - November 16 at 9:51 AM
rttnews.com logoMerck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up
www.rttnews.com - November 15 at 9:52 AM
finance.yahoo.com logoMerck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE
finance.yahoo.com - November 14 at 10:18 AM
finance.yahoo.com logo8:01 am Merck KGaA announces the results of the ADDRESS II Phase IIb, multicenter study on atacicept in patients with systemic lupus erythematosus; primary endpoint not met in overall study population
finance.yahoo.com - November 14 at 10:18 AM
finance.yahoo.com logoMerck KGaA, Darmstadt, Germany, Presents Phase II Data on the Safety and Efficacy of Atacicept at the 2016 ACR/ARHP Annual Meeting
finance.yahoo.com - November 2 at 9:42 AM
finance.yahoo.com logoMerck KGaA, Darmstadt, Germany Partners with American Cancer Society to Address Cancer in Women
finance.yahoo.com - November 1 at 6:27 PM

Social

Chart

Merck KGaA (MKGAY) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff